Bispecific antibodies
The concept of using bispecific antibodies for cancer therapy by retargeting immune effector cells was developed more than 25 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe side effects and the immunogenicity of the bispecific antibodies. A...
| الحاوية / القاعدة: | Springer ebooks. |
|---|---|
| مؤلف مشترك: | |
| مؤلفون آخرون: | |
| التنسيق: | Electronic Resource |
| اللغة: | English |
| منشور في: |
Berlin, Heidelberg
Springer Berlin Heidelberg
c2011
|
| الموضوعات: | |
| الوصول للمادة أونلاين: | Available for University of the Philippines Diliman via SpringerLink. Click here to access |